About us

Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease.

Our pipeline

Discovering targeted medicines

Our lead oncology asset, RXC004, is in Phase 2 in patients with advanced malignancies. The Company’s ROCK2 selective inhibitor, RXC007, is in a Phase 1 clinical study.

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets. These strengths have been recognised by others, and we have successfully completed a number of partnering deals including:

  • AstraZeneca (Porcupine inhibitor, AZD5055 previously RXC006) – now in Phase 1 clinical studies
  • Jazz Pharmaceuticals (Pan-RAF inhibitor, JZP815) – ready to enter Phase 1 clinical studies
  • Jazz Pharmaceuticals, ongoing oncology research collaboration in MAPK pathway
  • Loxo Oncology /Eli Lilly (BTK inhibitor, Pirtobrutinib/LOXO-305 previously RXC005) now in multiple Phase 3 clinical studies

Redx research headquarters in Mereside, Alderley Park

View in maps

Our team

Our team of over 70 in-house scientists is based at our headquarters at Alderley Park, Cheshire, the UK’s largest single site life science campus* (near to Manchester). The team is made up of world class medicinal chemistry, biology and clinical capabilities with deep-rooted biotech and large pharma experience, having generated numerous drug candidates and progressed them through discovery and into the clinic.

*Source: https://www.alderleypark.co.uk/science

Business model and strategy

Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. Our goal is to become a leading biotechnology company through the development of novel and differentiated targeted medicines in cancer and fibrotic disease and to progress best-in-class product candidates that will transform the lives of patients. The key elements of our strategy are:

  • Advance the development of RXC004, a Porcupine inhibitor, through clinical trials in our initial indications and then for the potential treatment of additional Wnt-ligand dependent tumors.
  • Advance the development of RXC007, a selective ROCK2 inhibitor, initially in clinical trials in idiopathic pulmonary fibrosis (IPF) and potentially in additional fibrotic indications.
  • Invest in our Redx discovery engine to expand our pipeline.
  • Maximise full potential of our product pipeline.

We intend to maximise the value of any particular product candidate by retaining development and commercialisation rights for the indications and geographies that we believe we can commercialise successfully on our own, pending regulatory approval. Alternately, we will continue to selectively evaluate partnerships to leverage the clinical and commercial expertise of large pharmaceutical companies, as we have successfully proven to date with AstraZeneca (RXC006 in fibrosis in 2020) and Jazz Pharmaceuticals (Pan-RAF inhibitor in 2019). Additionally, we may choose to evaluate in-licensing opportunities that are complementary to our strategic focus and can be leveraged by our capabilities.

Our discovery business model incorporates our in-house experience and an extensive network of specialist contractors. Our approach is based on three steps:

  1. Target: With the goal of de-risking our programmes, we select biologically or clinically validated targets where we believe there is an opportunity to successfully apply our drug discovery  capabilities in diseases of high unmet medical need.
  2. Design: Create molecules with differentiated properties, leveraging our design frameworks and our strength and experience in medicinal chemistry and translational biology to optimise a novel differentiated molecule for the target.
  3. Deliver: Focus our differentiated, targeted small molecules towards commercially attractive markets in which we believe we can be successful.